#WindwardBio
BIOTECH · Windward Bio debuts on Nasdaq, jumps 68% despite thin data

The Swiss asthma drug developer's stock soared past its IPO price, even though its lead drug has no proof yet that it prevents attacks.

Read the full story →

#Biotech #WindwardBio #TheDailyFathom
November 16, 2026 at 12:30 AM
Windward Bio's Nasdaq debut funds an ambitious clinical pipeline with no product revenue yet Windward Bio raised capital for asthma, COPD and dermatitis programs in a Nasdaq IPO,...

https://www.narrowit.com/news/windward-bio-nasdaq-ipo-clinical-pipeline-2026-11-15
#WindwardBio #WWB #IPO #Nasdaq
Windward Bio Nasdaq IPO funds asthma and COPD pipeline | Narrowit.com
Windward Bio priced 10.3 million shares at $17 and plans to direct proceeds to WIN378 and WIN027 trials, while warning of continuing losses.
www.narrowit.com
November 15, 2026 at 11:23 AM
#Swissbiotech #WindwardBio has raised $175 million in its #Nasdaq #IPO as it prepares to take on some heavyweight rivals with its TSLP-acting drug for inflammatory #respiratory and #dermatological diseases.

pharmaphorum.com/news/windwar...
Windward Bio catches $175m from its IPO
Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.
pharmaphorum.com
November 13, 2026 at 1:44 PM
Swiss biotech #WindwardBio is planning to take on some heavyweight rivals with its #TSLPactingdrug for inflammatory #respiratory and #dermatological diseases – a mission that will be helped by adding $165 million in crossover #financing to its cash reserves.

pharmaphorum.com/news/windwar...
May 8, 2026 at 10:21 AM